In 2022, the Global Digital Phenotyping and Digital Biomarkers Market was valued at USD 1.57 Billion and is projected to reach a market size of USD 3.46 Billion by 2030. Over the forecast period of 2023-2030, the market is projected to grow at a CAGR of 10.4%. Increasing smartphone penetration with high-speed network connectivity solutions, rapidly increasing uptake of wearable devices, increase in the prevalence of diseases and the growing geriatric population, significant product launches, and regulatory flexibility toward digital health solutions are majorly driving the growth of the market.
Industry Overview:
Biomarkers are objective measures that capture anatomic, physiological, and pathological characteristics to understand the health of an individual and the warning signals being given by the body. Digital biomarkers are quantifiable behavioral and physiological data collected and measured by digital devices such as portables, wearables, and implantables. Digital biomarkers offer significant imaging capabilities with an enhanced spatial resolution. Digital phenotyping is the extraction of information from data streams and digital devices to create personalized real-time analysis, thereby helping to provide accurate data. Digital phenotyping can identify traits and patterns in the population by utilizing their active or passive data and devise the treatment strategies for mental disorders effectively. Neurological and Psychiatric diseases present with complex, fluctuant, atypical symptoms in disease progression and display high variableness between patients. Traditional diagnostic and efficacy evaluation methods often depend on in-clinic visits and subjective evaluation by caregivers, clinicians, and patients. In-clinic evaluation methods are often time-consuming, costly, and limited in their quality and quantity of observations. In addition, they are prone to high-inter and intra-rater variability. The traditional diagnosis methods have some drawbacks that can affect the diagnostic process in the early stage of a disease which has a lag between the onset of the pathological process and the onset of disease symptoms. Data related to health being collected by smartphones provide a promising complementary approach to in-clinic assessments and can enhance patient care and treatment outcomes. Digital biomarkers provide a frequent assessment of a larger target population over long periods. An increase in the use of smart wearables and connected devices helps in the measurement of a range of diagnostic parameters for diseases including diabetes, mental health, cardiovascular, and neurological diseases. The emergence of smartwatches and the rising usage of smartphones aid in tracking the physiological data related to health.
The rapid development of telecom and IT infrastructure is boosting market growth. Digital monitoring of patients in their everyday life using smart technologies is rapidly evolving and may help assist clinicians in facilitating early diagnosis and evaluation interventions. Smart sensor technology to monitor patients is emerging rapidly. Modern smartphones and smart wearables are equipped with various sensors including acceleration, GPS, gyroscope, barometer, temperature, and health sensors. Digital biomarkers are such health-related information being collected in clinical trials. They offer objective, invaluable, and ecologically valid information for a better understanding of specific diseases. The rising government investments in the digitalization of the healthcare sector and the development of smart hospitals are anticipated to spur the market demand for digital phenotyping and digital biomarkers. The market is highly influenced by various developmental strategies adopted by numerous market players.
COVID-19 impact on Digital Phenotyping and Digital Biomarkers Market
The COVID-19 pandemic has significantly impacted the Digital phenotyping and digital biomarkers market. The COVID-19 outbreak escalated the demand for digital phenotyping and digital biomarkers as it helps in screening and diagnosis. Digital phenotyping and digital biomarkers offer the real-time analysis of data and helped doctors to carry out the data collection process remotely during the pandemic. There was a sudden increase in the market demand. An increase in remote patient monitoring and growing health concern among people propelled the development and validation of digital phenotyping and digital biomarkers during the COVID-19 pandemic. They can help in identifying patients who are at risk of diseases, by continuously monitoring disease symptoms or progression using data collected from an individual’s smart device.
MARKET DRIVERS:
Increasing smartphone penetration with high-speed network connectivity solutions and rapidly increasing uptake of wearable devices are fuelling the market growth
The advent of connected devices such as smart wearables, portable devices, and biosensors has significantly enabled the measurement of various parameters for detecting novel biomarkers. Mobile health apps include various physiological parameters such as sleep, activity, heart rate, and others. Biochemical parameters include metabolites, electrolytes, proteins, and small molecules. This provides huge opportunities to revolutionize the process of data capture and collection during clinical trials. The increase in the usage of connected devices and health-related mobile applications aids in the diagnostic and prognostic measurements of diverse diseases which, in turn, is likely to boost the market growth of digital phenotyping and digital biomarkers. The growing use of mobile devices generates a vast amount of personalized data including location, physical movement, information about vital health signs, and social media habits that can be processed by data mining. According to Pew Research Center, smartphone ownership grew from 35% in 2011 to 85% in 2021 in the United States. Additionally, smartphone ownership amongst the United States citizens aged 65+ grew from 3% in 2013 to 12% in 2021. Technological advances in the ranges of mobiles and digitally connected devices are further fuelling the market growth.
Significant product launches and regulatory flexibility toward digital health solutions are contributing to the market growth
An increase in product launches and FDA approval also drive the market growth. FDA has simplified the entry process for companies operating in the digital phenotyping and digital biomarkers market by modifying its guidelines related to software-as-medical-device. The FDA launched the Pre-Cert model, which aimed to streamline the regulatory process and boost innovation of digital health technologies. This flexibility in regulations toward digital health solutions is anticipated to propel the market growth of Digital Phenotyping and Digital Biomarkers.
An increase in the prevalence of diseases and the growing geriatric population is fuelling the market demand
According to the United States Centers for Disease Control and Prevention (CDC), the leading causes of disability and death in the U.S. costs USD 3.8 trillion in annual healthcare costs of the country. The increasing prevalence of chronic diseases globally and the growing geriatric population is rising the demand for efficient treatment and technologies to reduce healthcare costs. Smart wearables and smartphones monitor the health status of users and provide detailed insights into inter-and intra-individual disease variability in daily life.
The increasing cost of drug development led to the need for other alternatives, of which digital phenotyping and digital biomarkers are significant.
The rising cost of research and development of drugs is resulting in the increased cost of drugs. In the recent past, the cost of drug development has increased by almost 145% and the rate of success of drug development has reduced to half. Presently, the approval rate for drugs that enter clinical development is less than 12%. The study of biomarkers may help target the pathway where research should be focused which can reduce the number of processes required for drug development and the overall cost can be reduced.
MARKET RESTRAINTS:
Challenges associated with test validation, and biases can hamper the digital biomarkers market growth
The clinical assessment of digital biomarkers and data platforms which includes apps and wearables is of utmost importance. The validation testing of the data collected from healthy individuals or the target population needs to be performed in a clinically relevant environment. The platform which assesses the data must be free from data bias as this can deteriorate the credibility of the data analysis and might even lead to failure in the process. It is necessary to remove such biases from the data or address them before analyzing the data.
Challenges associated with integration, usability, and cost can restrain the market growth
Interoperability and integration are the most important parameters to be considered while developing digital health services. It needs to be assured by the service providers that the data collected can be shared across hospitals, labs, clinics, pharmacies, and patients irrespective of the application vendor. Also, the cost versus benefit analysis of digital phenotyping and digital biomarkers solutions must be done appropriately considering the nascent stage of the market.
DIGITAL PHENOTYPING AND DIGITAL BIOMARKERS MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2022 - 2030 |
|
Base Year |
2022 |
|
Forecast Period |
2023 - 2030 |
|
CAGR |
10.4% |
|
Segments Covered |
By Component, Application, End User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Akili Interactive Labs, ActiGraph, LLC., Fitbit, Inc., AliveCor, Inc., Novartis, Sanofi, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceuticals, HumanAPI, GlaxoSmithKline Plc, Mindstrong Inc., Sharecare, Inc., Alphabet, Inc., Onnela lab, Verily Life Science LLC |
This research report on the global digital phenotyping and digital biomarkers market has been segmented and sub-segmented based on component, application, end-user, and region.
Data Collection Tools
Digital Platforms
Mobile Apps
Desktop-based Software
Wearables
Biosensors
Data Integration Systems
Based on Component, the Digital Phenotyping and Digital Biomarkers Market is segmented into Data Collection Tools and Data Integration Systems. The Data Collection Tools segment held a significant revenue share in the global market and is anticipated to sustain its dominance during the forecast period. This is attributed to the increased adoption of smartphones and wearables that significantly help in data collection. The internet and wireless connectivity are major tools that facilitate easy data collection and data transfer. Biosensors account for a major portion of the data collection tools. The Data Integration Systems segment is anticipated to grow with the highest CAGR of 42% during the forecast period.
Sleep and Movement
Mood and Behavior
Neurodegenerative Disorders
Cardiological Diseases
Diabetes
Chronic pain
Respiratory Conditions
Gastrointestinal Diseases
Others
Based on Application, the Digital Phenotyping and Digital Biomarkers Market is segmented into Sleep and Movement, Mood and Behavior, Neurodegenerative Disorders, Cardiological Diseases, Diabetes, Chronic pain, Respiratory Conditions, Gastrointestinal Diseases, and Others. The Cardiovascular diseases segment dominates the global market in terms of revenue and is anticipated to sustain its dominance during the forecast period. This is attributed to the increased prevalence of cardiovascular diseases globally. According to WHO, cardiovascular diseases account for 32% of global deaths.
The Respiratory Conditions segment is estimated to be the fastest-growing segment during the forecast period owing to the rising prevalence of respiratory diseases like chronic obstructive pulmonary disease and asthma. The Neurodegenerative Disorders segment is estimated to have significant growth during the forecast period owing to an increase in the prevalence of neurological disorders and the rising adoption of digital phenotyping technology for mental health.
Biopharmaceutical Companies & labs
Insurance Payers
Healthcare Providers
Based on End-User, the Digital Phenotyping and Digital Biomarkers Market is segmented into Biopharmaceutical Companies & labs, Insurance Payers, and Healthcare Providers. The Biopharmaceutical Companies & labs segment dominates the market share and is anticipated to hold the largest revenue during the forecast period. The Insurance Payers segment is estimated to grow at the highest rate, around 43% during the forecast period.
North America
Europe
Asia-Pacific
Latin America
The Middle East
Africa
Geographically, the North American Digital Phenotyping and Digital Biomarkers Market holds the largest market share and is anticipated to account for a significant revenue share in the global market during the forecast period. The key factors contributing to this growth are the huge geriatric population, significant product launches, higher adoption rate of digital technologies, increase in investments in research & development, increased healthcare expenditure, growing approval of smart devices in this region, and the strong presence of key market players.
The European Digital Phenotyping and Digital Biomarkers Market held the second-largest share in the global market and is poised to expand at a significant growth rate during the forecast period owing to the rising demand for mobile health apps, and increased adoption of smartphones and wearable technology in healthcare.
The Digital Phenotyping and Digital Biomarkers Market in the Asia Pacific accounted for a major market share and is anticipated to witness a higher CAGR during the forecast period owing to the surge in the usage of smart devices, the proliferation of the digital technologies, increase in the patient pool, rising focus on enhancing healthcare facilities by the government, and growing focus of market players to leverage growth opportunities in this region. In addition, the growing geriatric population in this region is anticipated to exponentially augment the demand for digital phenotyping and digital biomarkers.
The Digital Phenotyping and Digital Biomarkers Market in Latin America, the Middle East, and Africa is anticipated to grow during the forecast period owing to increasing cases of chronic diseases, the growing need to manage healthcare costs and the increasing use of smartphones and the internet.
Major Key Players in the Market
Companies like
The global digital phenotyping and digital biomarkers market is dominated by plenty of digital health companies that can be categorized as developers of sensors and tools that collect and integrate patient-level data. Prominent players in the digital phenotyping and digital biomarkers market are engaged in synergistic activities, innovative product launches, acquisitions, collaborations with research and medical institutions, business expansion, and funding activities to expand the digital phenotyping and digital biomarker space.
Notable happenings in the Global Digital Phenotyping and Digital Biomarkers Market in the recent past:
Partnership- In March 2021, Human API partnered with CLEAR to empower the safe re-opening of businesses using secure COVID tests and vaccine data. Health Pass is a mobile application that makes it easier and safer for people to connect members' identities to COVID-related information.
Partnership- In March 2021, Wellstar Health System, one of Georgia's largest and most integrated healthcare systems, announced a strategic partnership with Sharecare, the digital health company that helps people manage all their health in one place. The partnership would offer market-leading innovations in personalized care delivery, population health, and consumer engagement.
Partnership- In April 2021, Winterlight Labs partnered with the Digital Medicine Society (DiMe) to drive the adoption of digital health resources.
Partnership- In March 2020, Vivoryon Therapeutics AG partnered with Winterlight Labs for the upcoming Phase 2b trial of PQ912 in Alzheimer’s clinical trial. Vivoryon Therapeutics will use the Winterlight speech-based biomarker and enhance novel therapy for Alzheimer’s disease.
Partnership- In September 2020, Jetstream APS partnered with Human API to enable life insurance applicants to digitally share access to their electronic health records (EHR).
Acquisition- In October 2020, Medidata, a Dassault Systemes company, the global leader in creating end-to-end solutions to support the clinical development process, announced the acquisition of the digital biomarker business of MC10. This will help Medidata to enhance remote biometric data capture capabilities in hybrid and virtual clinical trials.
Collaboration- In October 2019, MC10, Inc., collaborated with the University of Rochester for the application of the FDA-approved BioStamp nPoint system for the collection of movement-related data to quantitatively access the progression of diseases such as Parkinson’s and Huntington’s disease.
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
